Manama, April 17 (BNA) The National Health Regulatory Authority announced today the licensing of the first injectable drug manufacturing site in the Kingdom of Bahrain.
Gulf Biotechnology, which was established in 2015 as part of a Bahraini-Saudi joint venture, will be awarded Good Manufacturing Practices (GMP) certification to begin production and marketing of sterile and injectable formulations subject to NHRA inspection.
Commenting on the impending inspection of the facility, Her Excellency Dr. Maryam Al Jalahma, CEO of the National Health Regulatory Authority said: “The authority will ensure that the injectable drug manufacturing site meets the necessary safety and quality standards in line with best pharmaceutical manufacturing practices.”
The 4,500 square meter facility is the first of its kind in the Middle East to manufacture injectable formulations – such as vials, ampoules and prefilled syringes. The facility will use BOSCH technology to create a fully automated production line expected to be commissioned later in 2022.
This is the second pharmaceutical manufacturing company to be licensed in the Kingdom. In 2019, the National Regulatory Authority for Professions and Services granted Bahrain Pharma a license to produce nutritional supplements. The facilities will prioritize the production of high-demand medicines that other Gulf companies do not currently manufacture.
M